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Skeletal resistance to parathyroid hormone (PTH) is well
known to the phenomenon in chronic renal failure patient,
but the detailed mechanism has not been elucidated. In the
process of analyzing an animal model of renal failure with
low bone turnover, we demonstrated decreased expression
of PTH receptor (PTHR) accompanying renal dysfunction in
this model. In the present study, we focused on the
accumulation of uremic toxins (UTx) in blood, and examined
whether indoxyl sulfate (IS), a UTx, is associated with PTH
resistance. We established primary osteoblast cultures from
mouse calvariae and cultured the cells in the presence of IS.
The intracellular cyclic adenosine 30,50 monophosphate
(cAMP) production, PTHR expression, and free radical
production in the primary osteoblast culture were studied.
We found that the addition of IS suppressed PTH-stimulated
intracellular cAMP production and decreased PTHR
expression in this culture system. Free radical production in
osteoblasts increased depending on the concentration
of IS added. Furthermore, expression of organic anion
transporter-3 (OAT-3) that is known to mediate cellular
uptake of IS was identified in the primary osteoblast culture.
These results suggest that IS taken up by osteoblasts via
OAT-3 present in these cells augments oxidative stress to
impair osteoblast function and downregulate PTHR
expression. These finding strongly suggest that IS
accumulated in blood due to renal dysfunction is at
least one of the factors that induce skeletal resistance
to PTH.
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Secondary hyerparathyroidism accompanying chronic renal
failure is a state of oversecretion of parathyroid hormone
(PTH). This is caused by reduced calcium absorption from
the intestinal tract due to lowered activity of 1a vitamin D
hydroxylase in the kidney, as a result of hyperphosphatemia
due to renal dysfunction. Moreover, in vitro experiments
using cell cultures have confirmed that phosphorus acts
directly on parathyroid cells stimulating PTH secretion.1,2 In
recent years, new drugs have been developed that allow
control of PTH oversecretion due to secondary hyerpar-
athyroidism. However, a level of PTH three times the normal
level is necessary to maintain normal bone turnover in
patients with renal failure.3 In addition, studies of bone
biopsies from dialysis patients have reported that patients
with subnormal PTH secretion have low bone turnover.
These phenomena are recognized as skeletal resistance to
PTH associated with renal failure.
The causes of PTH resistance have been investigated and
several factors have been reported. Lowered PTH receptor
(PTHR) gene expression in patients with renal failure has
been proven by in situ hybridization of bone biopsy tissues.4
Other studies showed that the 7–84 PTH fragment accumu-
lates in the serum of renal failure patients and inhibits
receptor binding of the native 1–84 PTH.5,6 Osteoprotegerin
is the decoy receptor of the osteoclast differentiation factor,
and osteoprotegerin has been reported to accumulate in the
serum of patients with renal failure.7–9 Accumulation of
osteoprotegerin in serum may inhibit the actions of PTH on
the bone. Furthermore, bone morphogenetic protein-7
produced in the kidney is a strong osteoblast differentiation
factor, and low serum bone morphogenetic protein-7 level
has been reported in renal failure.10 It is speculated that low
bone morphogenetic protein-7 level may lead to reduced
number of osteoblasts and lowered PTH response.
As a model of skeletal PTH resistance, we have previously
developed an animal model of renal failure without
secondary hyerparathyroidism and reported our analysis of
the bone metabolism in this model.11 Our results demons-
trated that bone turnover is lowered in renal failure with no
secondary PTH oversecretion, and confirmed that the
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expression of the PTHR gene is downregulated in bone.
These results indicate that skeletal PTH resistance is present
even in renal failure with normal PTH secretion, as is
observed in osteitis fibrosa associated with secondary
hyerparathyroidism. Furthermore, we demonstrated that
bone turnover is lowered dependent on the degree of renal
dysfunction. From these results, we speculated that the
uremic toxins (UTx) accumulated in blood as a result of
lowered renal function may be associated with PTH
resistance.
A diversity of UTx accumulates in the blood of patients
with impaired renal function. Among them, indoxyl sulfate
(IS) is produced as from the metabolism of dietary
tryptophan in the body.12 Studies so far have shown that IS
accumulates in blood and promotes the progression of renal
dysfunction.13,14 IS is taken up by cells via the organic anion
transporter (OAT) especially present in proximal tubular cells
of the kidney,15–19 and induces cytotoxicity.16,17 Compared
with other UTx, such as b-aminoisobutylic acid, guanidino-
succinic acid, hippuric acid, and p-hydroxyhippuric acid, IS
at low concentrations produces higher levels of free radicals
and stronger cytotoxicity than the other UTx.17 Moreover,
administration of an oral adsorbent that adsorbs indole, the
precursor of IS, suppressed the progression of renal fail-
ure.20–22 We recently reported that when rats with renal
dysfunction and low bone turnover were administered an
oral adsorbent, blood IS level was reduced and osteoblastic
cell function was improved.23 We also observed improvement
of the suppressed PTHR gene expression in bone, which is
implicated as a cause of PTH resistance. The results of these
animal experiments strongly suggest that IS exerts some
effects on osteoblastic cells or is involved in PTH resistance.
We therefore focused on IS as a representative of UTx.
In the present study, we aimed to examine whether IS is
associated with skeletal resistance to PTH by studying the
effects of IS using cultured osteoblastic cells.
RESULTS
Effect of IS on PTH action in primary cultured osteoblastic
cells
To elucidate whether IS is involved in skeletal resistance to
PTH, we first examined its effect on PTH signaling pathways
in primary cultured osteoblastic cells derived from mouse
calvariae. Eight wells were tested for each condition. As
shown in Figure 1a, cyclic adenosine 30,50 monophosphate
(cAMP) production was seven times higher when the cells
were stimulated with 10–8 mmol/l of PTH compared to non-
stimulated cells. cAMP production was diminished by
pretreatment with IS in a dose-dependent manner. Pretreat-
ment with 2 mmol/l IS significantly suppressed PTH-
stimulated cAMP production compared to non-IS-treated
controls (Figure 1a). IS has been reported to be taken up into
cells by OAT.15–19 To confirm that OAT is involved in IS
uptake into osteoblasts, we added probenecid, a transporter
inhibitor, to the cells during pretreatment with 2 mmol/l of
IS. In the presence of 20 mmol/l of probenecid, the inhibition
of cAMP production by IS was partially abrogated (Figure
1b). The results were almost unchanged when performed in
the presence and absence of albumin (data not shown).
Next, we examined PTHR gene expression. As shown in
Figure 2, PTHR mRNA level was inhibited significantly by
treatment with 2 mmol/l of IS for 24 h. Furthermore, the
inhibition was dose dependent at 48 h of IS treatment (Figure
2a and b), and PTHR gene expression was inhibited
significantly by 0.5 mmol/l of IS. The results were almost
unchanged when performed in the presence and absence of
albumin (data not shown). Addition of 20 mmol/l of
14
12
10
8
6
4
2
0
14
12
10
8
6
4
2
0
0 0 2 2 IS (mmol/l)
IS (mmol/l) +20 mmol/lprobenecid
0.125 0.25 0.5 1.0 2.0
*
*
ba
Fo
ld
 in
du
ct
io
n
Fo
ld
 in
du
ct
io
n
Figure 1 | Effect of IS on PTH-induced intracellular cAMP
production in primary osteobalstic cell cultures. (a) Primary
osteoblastic cell cultures pretreated for 24 h with indicated
concentrations of IS were stimulated with PTH for 10 min and then
intracellular cAMP production was measured. cAMP concentration
was adjusted by protein concentration per well, and is expressed as
fold induction compared to baseline. Open bar is negative control
without addition of PTH or IS. Data are presented as meanþ s.d. of
eight wells. *Po0.05 vs 0 mmol/l IS (b) cAMP production upon
pretreatment with 2 mmol/l of IS in the presence of probenecid, a
transporter inhibitor. Shaded bar shows cAMP production in the
presence of 20 mmol/l of probenecid. Data are presented as
meanþ s.d. of eight wells. *Po0.05 vs 2 mmol/l IS. IS: indoxyl sulfate
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Figure 2 | Changes in expression of the PTHR gene in primary
osteobalstic cell cultures by the addition of IS. All experiments
were repeated three times and the representative data are shown.
(a) Expression of PTHR gene upon treatment with various
concentrations of IS for 12, 14, or 48 h. (b) Fold induction of PTHR
gene expression compared to beta-actin. *Po0.05 vs 0 mmol/l of IS.
(c) Expression of PTHR gene upon treatment with 2.0 mmol/l of IS for
48 h in the presence of probenecid, a transporter inhibitor.
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probenecid to 2 mM of IS partially reversed the inhibition of
PTHR gene expression as shown in Figure 2c.
Gene expression of OATs in osteoblastic cells
As past studies have reported that IS has high affinity to
OAT-1 and OAT-3 in renal tubular cells,18,19 gene expression
of OAT-1 and OAT-3 was determined by reverse transcrip-
tase-polymerase chain reaction (PCR) using RNA extracts.
Expression of OAT-3 was observed, whereas no expression of
OAT-1 was detected in primary cultured osteoblastic cells
(Figure 3).
Uptake of IS in osteoblasts
After confirming the expression of OAT-3 gene in cultured
osteoblastic cells, we measured the amount of intracellular
uptake of IS by high-performance liquid chromatography
analysis. Cellular uptake of IS increased in a time-dependent
manner and the uptake was significantly suppressed by the
addition of a specific transporter inhibitor, probenecid
(Figure 4). The results were almost unchanged when
performed in the presence and absence of albumin (data
not shown).
Assessment of intracellular oxidative stress
As shown in Figure 5, IS increased cellular oxidative stress in
a dose-dependent manner. Addition of antioxidants or
transporter inhibitor suppressed free radical production
(Table 1). The results were almost unchanged when
performed in the presence and absence of albumin (data
not shown).
Effect of IS on cell viability in mouse primary osteoblastic cell
culture
To determine cytotoxicity, the effect of IS on cell proliferation
of mouse calvaria primary osteoblastic cell culture was studied
by 3-[4,5-dimethylthiazol-2-yl]-2, 5-diphenyl-tetrazolium
bromide assay. As shown in Figure 6, IS inhibited cell
proliferation at the concentration range of 0.5–2 mmol/l. The
results were almost unchanged when performed in the
presence and absence of albumin (data not shown).
DISCUSSION
Bone metabolism in patients with renal failure is characteri-
zed by skeletal PTH insufficiency, so-called PTH resistance,
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Figure 3 | Expression of the OAT gene in primary osteobalstic cell
cultures. The methods were as described in Materials and Methods.
The experiment was repeated three times and a representative gel is
shown. OAT; organic anion transporter.
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Figure 4 | Intracellular IS concentrations in primary osteobalstic
cell cultures. The data are presented as meanþ s.d. of eight wells.
IS at 1 mmol/l was added to the cell cultures and the intracellular IS
concentrations were measured with time. Open bar shows the
intracellular IS concentration in cells incubated with 1 mmol/l of IS in
the presence of probenecid, a transporter inhibitor, for 60 min.
*Po0.05; vs 0 min, **Po0.05 vs 60 min with addition of IS only.
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Figure 5 | Free radical production induced by the addition of IS.
The data represent meanþ s.d. of eight wells. Primary osteoblastic
cells were seeded in 96-well plates. IS was added and free radical
production was measured after 6 min. Menadione was used as
positive control, because the free radicals produced by IS and
menadione are both hydroxyl radicals. *Po 0.05 vs 0 min, IS: IS.
Table 1 | Free radical production induced by the addition of
indoxyl sulfate
Indoxyl sulfate Relative fluorescene (%)
1 mmol/l 300724*
1 mmol/l (+Probucol 62.5mmol/l) 180721#
1 mmol/l (+NAC 2.5 mmol/l) 120718#
1 mmol/l 30072*
1 mmol/l (+Probenecid 10 mmol/l) 14072#
1 mmol/l(+Probenecid 20 mmol/l) 8072#
0 mmol/l 10070
NAC, N-acetyl-cysteine.
*Po0.01 vs 0 mmol/l, #Po0.05 vs 0 mmol/l.
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which presents various pathological states depending on the
serum concentrations of PTH and activated vitamin D3.
Although recent development of various drugs now permits
the control of PTH oversecretion in renal failure, the problem
of skeletal resistance to PTH remains unsolved.
We have developed an animal model of renal failure with
low bone turnover. During analysis of the bone of this model,
we found decreased PTHR expression in the bone and
confirmed the presence of skeletal resistance to PTH in low
turnover bone of renal failure animals.11 However, the factors
that cause the deceased expression of PTHR remain
unelucidated. Our finding that downregulation of PTHR in
bone depends on the degree of renal dysfunction led us
speculate that uremic substances accumulated in blood due
to renal failure may be involved. Furthermore, we have
recently reported that preventing accumulation of IS in blood
improves bone formation and improves the inhibited PTHR
gene expression.23 Therefore, in the present study, we focused
on IS that has been reported to accumulate in blood during
renal failure, and studied whether this substance is associated
with skeletal resistance to PTH.
Our results showed that culture of primary osteoblastic
cells in the presence of IS suppressed the intracellular cAMP
production stimulated by PTH. This suppression was
dependent on the concentration of IS added; especially, a
significant decrease was observed at 2 mmol/l. In addition, we
also demonstrated that the addition of IS decreased PTHR
mRNA expression in osteoblasts in a time-dependent and
concentration-dependent manner. These observations sug-
gest a possibility that PTH resistance induced by the presence
of IS may be mediated by downregulation of PTHR
expression in bone. Human study using bone biopsy samples
of renal failure patients4 and our animal model of renal
failure with low bone turnover11 both showed downregula-
tion of PTHR expression in bone. Therefore, we speculate
that downregulation of PTHR expression is caused by the IS
accumulated in blood as a result of renal insufficiency.
It has been reported that in the proximal tubules of the
kidney, IS is taken up by the tubular cells via OAT-1 and
-3.15–19 We identified the presence of OAT-3 gene in
osteoblasts and demonstrated that the intracellular concen-
tration of IS increased in a time-dependent manner. More-
over, in the presence of a transporter inhibitor, the
intracellular IS concentration decreased and the inhibition
of cAMP accumulation was mitigated. These results strongly
suggest that IS is taken up by osteoblasts via OAT-3 present in
these cells.
The free radical species produced in cells when stimulated
by IS has been identified to be hydroxyl radicals.17 Owada
et al. (J Am Soc Nephrol 2003; 14: 664 (abstract)) conducted
an ex vivo electron spin resonance spectroscopy study and
reported that IS lowers the superoxide scavenging activity in
the kidney, causes a delay in clearance of free radicals in the
body, and increases the oxidative stress load. Recently,
Gelasco and Raymond24 reported that IS sulfate augments
extracellular SOD-sensitive O2- production and intracellular
hydroxyl radical production in mesangial cells. In addition,
oxidative stress induced by hydrogen peroxide25–27 and
menadione28 has been reported to inhibit growth and
mineralization of osteoblast. In the present study, free radical
production in cultured osteoblasts was increased depending
on the concentration of IS added, as shown in Figure 5. At
the same time, IS sulfate-induced free radical production was
suppressed by the addition of antioxidants and free radical
scavenger, and inhibition was also obtained by the addition of
probenecid, a transporter inhibitor (Table 1). These results
verify that the same phenomena observed in proximal renal
tubular cells occur also in osteoblasts. In other words, they
suggest that IS taken up by osteoblasts via OAT-3 increases
intracellular oxidative stress leading to osteoblast dysfunc-
tion.
In our previous study using a renal failure rat model with
low turnover bone, we observed cytotoxicity to osteoblasts
during 6 weeks.11 When we attempted long-term culture of
mouse primary osteoblastic cells to examine the effect of IS at
a concentration similar to the blood level in dialysis patients,
the cultures could not be maintained for more than 3 weeks.
Therefore, it was not possible to examine the long-term effect
of low concentration of IS. On the other hand, short-term
exposure to low concentration of IS had no significant effect
on osteoblastic cells. In a recent study, we demonstrated that
the blood IS level increased with time in rats with renal
failure.23 From these findings, we presumed that the
cytotoxic effect of IS depends on the product of concentra-
tion and time of exposure. As the objective of the present
study was to examine the mechanism of action of IS on
osteoblastic cells, we considered it necessary to design the
experiment using a high concentration of IS for a short
exposure duration.
A large variety of UTx accumulate in blood during renal
failure. UTx are classified by molecular weight and mode of
protein binding.29 However, except for IS and a few other
substances, the detailed effects of these toxins are largely
unknown. Osteoblasts are also affected by uremic serum.
Addition of serum from dialysis patients to cultured
osteoblasts decreased PTHR expression30 and induced
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Figure 6 | Effect of IS on viability of primary mouse osteoblastic
cell culture. Cell number was measured 24 h after the addition of IS
at indicated concentrations, and expressed as the percentage of
control cells not pretreated with IS (open bar). The data represent
meanþ s.d. of eight wells. *Po0.05 vs 0 mM IS-treated cells, IS: indoxyl
sulfate.
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osteoblast dysfunction including impaired IL-6 secretion.31
However, these studies did not identify the substances that
induce these effects. An animal study reported that admin-
istration of two UTx, indoleacetic acid, and hippuric acid, to
animals with lowered renal function accelerated the progres-
sion of renal failure. It is possible that other organic anionic
UTx that depend on OAT for uptake may exert similar effects
on osteoblastic cells, although the cytotoxicity of the UTx
may depend on its affinity to OAT.
In summary, the UTx IS is taken by osteoblasts via OAT-3
present in these cells, where it augments free radical
production inside the cells and induces osteoblast dysfunc-
tion including decreased expression of PTHR. As decreased
PTHR is associated with decreased response to PTH, these
observations suggest that IS accumulated in blood due to
renal failure may be one of the factors inducing skeletal
resistance to PTH. IS is a surrogate compound of organic
anionic UTx. Many other types of UTx apart from organic
anionic compounds accumulate in the patients’ blood and
these diverse UTx are probably also involved in the
development of low turnover bone in dialysis patients.
Further studies of the effects of UTx, including organic
anionic compounds other than IS, individually and in
combination, would elucidate the detailed mechanism of
development of low turnover bone and PTH resistance.
MATERIALS AND METHODS
Primary culture of osteoblastic cells
Osteoblastic cells were isolated from calvariae of neonatal mice
littermates as described previously.32 Seven-day-old mice, delivered
by timed pregnant mice (Nihon Clea, Tokyo), were killed and the
calvariae aseptically harvested and dissected free of suture tissue
without disturbing the periosteum. Dissected neonatal mouse
calvariae were then washed in phosphate-buffered saline and
digested with 1 ml trypsin/EDTA containing 10 mg collagenase
(Collagenase P, Roche Applied Science, Indianapolis, IL, USA) five
times for 10 min each. And cells from fractions 3 to 5 were pooled.
Cells were seeded in 6-well dishes at a density of 5000 cells/cm2 and
grown to confluency (in 5–7 days) in alpha minimal essential
medium containing 1 mg/ml bovine serum albumin and 100mg/ml
L-ascorbic acid phosphate and subsequently treated with the various
bone resorptive factors. Then we identified the cells in this fraction
as osteoblastic cells using alkaline phosphate staining (data not
shown).
cAMP generation assay
To study the effect of IS on the PTH response of primary osteoblast
cultures, intracellular cAMP production was measured. Osteoblastic
cells (1 103 cells/well) were plated and allowed to grow until
80–90% confluency. After 24-h pre-incubation with various
concentrations (0–2 mmol/l) of IS (Sigma, St Louis, MO, USA) in
the medium, the cells were incubated with 108 mol/l PTH for
10 min. cAMP production was measured using the Tropix cAMP-
screen (Applied Biosystems, Foster City, CA, USA) according to the
manufacturer’s protocol. In addition, we examined the effect of the
addition of 20 mmol/l of probenecid on cAMP production.
Probenecid (Sigma) was dissolved in weakly alkaline water and
then added to the medium. The pH of the medium was checked
after addition of probenecid to confirm that there was no change in
pH before the experiment was started. The data obtained were
adjusted by the cell protein concentration per well and then
expressed in fold induction compared to baseline.
RNA isolation, cDNA synthesis, and PCR analysis
Total RNA was isolated using RNeasy Mini Kit (QIAGEN, Tokyo,
Japan) according to the manufacturer’s instruction. Total RNA
(1mg) was used as the template for cDNA synthesis in a 20ml
volume using an reverse transcriptase-PCR kit (Invitrogen, Carls-
bad, CA, USA) according to the manufacture’s instructions. Real-
time PCR was performed on a Light Cycler (Roche, Basal,
Switzerland). The PCR reactions consisted of AmpliTaq Gold PCR
Master Mix (Applied Biosystems), 0.1 mM specific primers, and 50 ng
of cDNA. Specific primers for mouse PTHR (50-GGT GTC CAC
TAC ACC GTC TTC-30 and 50-TGT TTC CCA TTC TTC CTG CAA
C-30), OAT1 (50-ATG CCT ATC CAC ACC CGT GC-30 and 50-GGC
AAA GCT AGT GGC AAA CC-30), OAT3 (50-CAG TCT TCA TGG
CAG GTA TAC TGG-30 and 50-CTG TAG CCA GCG CCA CTG AG-
30) were designed according to previous studies,15,33–35 and beta-
actin (50-TCA TGA AGT GTG ACG TTG ACA TCC GT-30 and 50-
CCT AGA AGC ATT TGC GGT GCA CGA TG-30) was purchased
from Promega (Madison, WI). The amplification reaction products
(10ml) were analyzed by agarose gel electrophoresis and visualized
by ethidium bromide staining.
Cellular uptake of IS
Cellular uptake of IS was estimated by the method described
previously.13 Briefly, IS at a final concentration of 1 mmol/l was
added to primary osteoblastic cell culture, and IS intake into the
cells was examined up to 60 min. The cells were washed in
phosphate-buffered saline and methanol was added to prepare a
cell extract. The amount of intracellular IS was determined by high-
performance liquid chromatography systems 10A (Shimadzu, Kyoto,
Japan).
Assessment of cellular oxidative stress
Cellular oxidative stress was assessed by the method described
previously.15,17 Primary osteoblastic cells were seeded in a 96-well
tissue culture plate at a density of 2 103 cells/well. After incubation
for 3 days, the cells were washed with 100ml D-phosphate-buffered
saline (Nacalai Tesque, Kyoto, Japan) containing 5 nmol/l D-glucose
and 20 mmol/l dihydro-fluorescein diacetate. IS at the indicated
amount was added to the wells. Fluorescence was measured using a
fluorescence plate reader (Spectromax GEMINI XS, Molecular
Devices, Sunnyvale, CA) at Exl 485 nm and Eml 538 nm at 0 min
and 60 min. Data were expressed as percent increase in fluorescence
intensity compared to the control experiment. We also examined the
free radical production in the presence of antioxidants, N-acetyl-
cysteine and probucol (Sigma). The free radicals produced in cells by
the addition of IS are known to be hydroxyl radicals.17,24 Therefore,
we used menadione that also produces hydroxyl radicals36 as
positive control.
Cytotoxicity assays
Cell viability was assessed using the 3-[4,5-dimethylthiazol-2-yl]-2,
5-diphenyl-tetrazolium bromide (DOJIN chemicals, Kumamoto,
Japan) assay as described previously.16 Primary osteoblastic cells were
incubated in a medium with or without IS at 371C for 48 h. After the
cells were lysed with isopropanol/hydrochloric acid solution, the
optical density was measured at 570 nm using the optical density at
630 nm as reference (Spectra Fluor; GmbH, TECAN, Austria).
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Statistical analysis
All data are expressed as mean7s.d. Means of groups were
compared by analysis of variance.
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